Chronic kidney disease (CKD) is a well-established risk factor for cardiovascular (CV) disease because declining kidney ...
Orlowski Calls Linvoseltamab Results “the Best Single Agent Data Ever In the History of Myeloma”
LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...
Chronic kidney disease (CKD) significantly amplifies cardiovascular (CV) risk, with CV disease remaining the leading cause of ...
The 5 most-read breast cancer articles on AJMC.com this year included FDA approvals, emerging therapies for metastatic breast ...
Tom Kim, MD, of Sound Long-Term Care Management, discusses how serious illness and care coordination set these ACO patients ...
FLAMeS, a new convolutional neural network, enhances MS lesion segmentation accuracy using only T2-weighted FLAIR images, ...
The FDA approved fam-trastuzumab derextecan-nki (Enhertu; Daiichi Sankyo, Inc), a HER2-directed antibody-drug conjugate (ADC), in combination with pertuzumab as a first-line treatment for patients ...
Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with ...
Previously, the FDA required that RWE submissions include private, confidential information at the individual patient level. This requirement made it impractical to use many large databases containing ...
Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, ...
These top 5 stories underscore how 2025 was a year of constant friction at the intersection of public health and political ...
Panelists discuss how schizophrenia typically evolves through distinct phases—from first-episode psychosis to chronic illness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback